+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Prognostic value of plasma neutrophil gelatinase-associated lipocalin in patients with heart failure



Prognostic value of plasma neutrophil gelatinase-associated lipocalin in patients with heart failure



Revista Portuguesa de Cardiologia 34(7-8): 473-478



Neutrophil gelatinase-associated lipocalin (NGAL) is an early marker of kidney injury. We sought to assess the prognostic value of this biomarker in patients with stable chronic heart failure (HF). We studied 61 patients with chronic systolic HF who had been receiving optimal medical treatment for at least six months. Biomarkers were measured at baseline and included plasma NGAL, microalbuminuria, serum creatinine, and B-type natriuretic peptide (BNP). Estimated glomerular filtration rate (eGFR) was also calculated. Mean follow-up was 10.6±6.6 months. The primary endpoint was time to first cardiovascular event, defined as a combination of cardiovascular death, HF hospitalization or emergency department visit due to HF. Variables independently related to events were determined using a Cox proportional hazards model. Fifteen (24.6%) patients reached the primary endpoint. Patients with events were more likely to have worse renal function at baseline and also higher NGAL levels (median 316 [interquartile range 122-705] vs. 107 [78-170]; p=0.006). NGAL correlated significantly with creatinine (r=0.50; p<0.0001), albuminuria (r=0.33; p=0.008), and eGFR (r=-0.47; p=0.0001) but not with BNP (r=0.003; p=0.97). The best NGAL cutoff as determined by ROC curve analysis was 179 ng/ml. Event-free survival was lower in patients with NGAL above this cutoff. Variables independently related to events were NGAL (HR 1.0035, 95% CI 1.0019-1.0052; p<0.0001) and male gender (HR 5.9, 95% CI 1.22-28.6; p=0.028). NGAL correlated with other biomarkers of renal function but not with BNP and was independently associated with outcomes.

(PDF emailed within 0-6 h: $19.90)

Accession: 058637945

Download citation: RISBibTeXText

PMID: 26162288

DOI: 10.1016/j.repc.2015.02.003


Related references

Prognostic value of plasma neutrophil gelatinase-associated lipocalin for mortality in patients with heart failure. Circulation. Heart Failure 7(1): 35-42, 2014

Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: the NGAL EvaLuation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial. European Journal of Heart Failure 13(8): 846-851, 2012

Prognostic Value of Urinary Neutrophil Gelatinase-Associated Lipocalin on the First Day of Admission for Adverse Events in Patients With Acute Decompensated Heart Failure. Journal of the American Heart Association 6(5), 2018

Prognostic value of neutrophil gelatinase-associated lipocalin in acute heart failure. International Journal of Cardiology 165(1): 51-55, 2014

Increased plasma neutrophil gelatinase-associated lipocalin levels predict mortality in elderly patients with chronic heart failure. Rejuvenation Research 12(1): 7-14, 2009

Plasma neutrophil gelatinase-associated lipocalin and long-term mortality in patients with acute heart failure and normal renal function. International Journal of Cardiology 214: 51-53, 2017

Neutrophil gelatinase-associated lipocalin as diagnostic and prognostic tool for cardiovascular disease and heart failure. Expert Opinion on Medical Diagnostics 7(2): 209-220, 2014

Plasma levels of neutrophil gelatinase-associated lipocalin in children with heart failure. Therapeutic Advances in Cardiovascular Disease 10(1): 30-36, 2016

Admission plasma neutrophil gelatinase associated lipocalin (NGAL) predicts worsening renal function during hospitalization and post discharge outcome in patients with acute heart failure. Acute Cardiac Care 16(3): 93-101, 2015

Neutrophil Gelatinase-Associated Lipocalin and depression in patients with chronic heart failure. Brain, Behavior, and Immunity 38: 59-65, 2014

Plasma Neutrophil Gelatinase-Associated Lipocalin and Predicting Clinically Relevant Worsening Renal Function in Acute Heart Failure. International Journal of Molecular Sciences 18(7), 2018

Experimental and Human Evidence for Lipocalin-2 (Neutrophil Gelatinase-Associated Lipocalin [NGAL]) in the Development of Cardiac Hypertrophy and heart failure. Journal of the American Heart Association 6(6), 2018

Plasma neutrophil gelatinase-associated lipocalin as a marker for the prediction of worsening renal function in children hospitalized for acute heart failure. Saudi Journal of Kidney Diseases and Transplantation 27(1): 49-54, 2016

Predictive value of plasma neutrophil gelatinase-associated lipocalin for acute renal failure in patients with severe sepsis. Journal of the Chinese Medical Association 79(8): 428-434, 2017

Renal Functions and Prognosis Stratification in Chronic Heart Failure Patients and the Importance of Neutrophil Gelatinase-Associated Lipocalin. Kidney & Blood Pressure Research 43(6): 1865-1877, 2018